Additional therapeutic strategies to target downstream apoptosis pathways include the use of either the caspase-9 inhibitor taurine or the caspase-3 inhibitor Z-DEVD-FMK, and these have been reported to show some therapeutic efficacy in a neuronal cell model of Niemann–Pick disease, type C1 [93]. This evidence concerns the gene CASP9 and Niemann-Pick disease type C.